{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:37:00Z","timestamp":1790005020873,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00430-016-0469-7","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T11:49:25Z","timestamp":1469706565000},"page":"575-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy"],"prefix":"10.1007","volume":"205","author":[{"name":"for Frankfurt HIV Cohort Study","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Donath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"St\u00fcrmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Bickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Khaykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"G\u00f6pel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"de Leuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundolf","family":"Sch\u00fcttfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3777-9006","authenticated-orcid":false,"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"469_CR1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00002030-200402200-00017","volume":"18","author":"C Stephan","year":"2004","unstructured":"Stephan C, von Hentig N, Kourbeti I et al (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir\/ritonavir. AIDS 18:503\u2013508","journal-title":"AIDS"},{"key":"469_CR2","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/jac\/dkl375","volume":"58","author":"S Staszewski","year":"2006","unstructured":"Staszewski S, Babacan E, Stephan C et al (2006) The LOPSAQ Study: 48-week analysis of a boosted double protease inhibitor regimen containing lopinavir\/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 58:1024\u20131030","journal-title":"J Antimicrob Chemother"},{"key":"469_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00430-012-0276-8","volume":"202","author":"C Stephan","year":"2013","unstructured":"Stephan C, Bartha V, Herrmann E, von Hentig N, Khaykin P, Knecht G, Gute P, Brodt HR, St\u00fcrmer M, Berger A, Bickel M (2013) Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy. Med Microbiol Immunol 202:117\u2013124","journal-title":"Med Microbiol Immunol"},{"key":"469_CR4","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","volume":"49","author":"Y Yazdanpanah","year":"2009","unstructured":"Yazdanpanah Y, Fagard C, Descamps D et al (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49:1441\u20131449","journal-title":"Clin Infect Dis"},{"key":"469_CR5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/QAI.0b013e3181b17f53","volume":"52","author":"A Imaz","year":"2009","unstructured":"Imaz A, del Saz SV, Ribas MA et al (2009) Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 52:382\u2013386","journal-title":"J Acquir Immune Defic Syndr"},{"key":"469_CR6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","volume":"24","author":"JR Arribas","year":"2010","unstructured":"Arribas JR, Horban A, Gerstoft J et al (2010) The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml. AIDS 24:223\u2013230","journal-title":"AIDS"},{"key":"469_CR7","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","volume":"24","author":"C Katlama","year":"2010","unstructured":"Katlama C, Valantin MA, Algarte-Genin M et al (2010) Efficacy of darunavir\/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS 24:2365\u20132374","journal-title":"AIDS"},{"key":"469_CR8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","volume":"101","author":"RB Kim","year":"1998","unstructured":"Kim RB, Fromm MF, Wandel C, Leake B et al (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289\u2013294","journal-title":"J Clin Invest"},{"key":"469_CR9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-1293.2012.00989.x","volume":"13","author":"JR Arribas","year":"2012","unstructured":"Arribas JR, Clumeck N, Nelson M et al (2012) The MONET trial: week 144 analysis of the efficacy of darunavir\/ritonavir (DRV\/r) monotherapy versus DRV\/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load\u00a0<\u00a050 HIV-1 RNA copies\/mL at baseline. HIV Med 13:398\u2013405","journal-title":"HIV Med"},{"key":"469_CR10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/QAD.0b013e32814e6b1c","volume":"21","author":"P Vernazza","year":"2007","unstructured":"Vernazza P, Daneel S, Schiffer V et al (2007) The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21:1309\u20131315","journal-title":"AIDS"},{"key":"469_CR11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789\u20131799","journal-title":"Neurology"},{"key":"469_CR12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/jac\/dkt538","volume":"69","author":"C Stephan","year":"2014","unstructured":"Stephan C, Hill A, Hadacek MB et al (2014) Performance of the Abbott RealTime HIV-1 assay versus the -Roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers. J Antimicrob Chemother 69:1708\u20131710","journal-title":"J Antimicrob Chemother"},{"key":"469_CR13","first-page":"137","volume":"19","author":"S Letendre","year":"2011","unstructured":"Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137\u2013142","journal-title":"Top Antivir Med"},{"key":"469_CR14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/01621459.1995.10476499","volume":"90","author":"MG Akritas","year":"1995","unstructured":"Akritas MG, Murphy SA, LaValley MP (1995) The Theil-Sen estimator with doubly censored data and applications to astronomy. J Am Stat Assoc 90:170\u2013177","journal-title":"J Am Stat Assoc"},{"key":"469_CR15","first-page":"1","volume":"36","author":"MP Fay","year":"2010","unstructured":"Fay MP, Shaw PA (2010) Exact and asymptotic weighted Logrank tests for interval censored data: the interval R package. J Stat Softw 36:1\u201334","journal-title":"J Stat Softw"},{"key":"469_CR16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/QAD.0b013e32832c4152","volume":"23","author":"CM Marra","year":"2009","unstructured":"Marra CM, Zhao Y, Clifford DB et al (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359\u20131366","journal-title":"AIDS"},{"key":"469_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre S, Marquie-Beck J, Capparelli E et al (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65\u201370","journal-title":"Arch Neurol"},{"key":"469_CR18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2377-11-148","volume":"11","author":"LA Cysique","year":"2011","unstructured":"Cysique LA, Waters EK, Brew BJ (2011) Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol 11:148","journal-title":"BMC Neurol"},{"key":"469_CR19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11904-015-0267-7","volume":"12","author":"F Ferretti","year":"2015","unstructured":"Ferretti F, Gissl\u00e9n M, Cinque P et al (2015) Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV\/AIDS Rep 12:280\u2013288","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4 Suppl 3","key":"469_CR20","doi-asserted-by":"crossref","first-page":"19788","DOI":"10.7448\/IAS.17.4.19788","volume":"17","author":"J Arribas","year":"2014","unstructured":"Arribas J, Girard PM, Paton N et al (2014) Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. J Int AIDS Soc 17(4 Suppl 3):19788","journal-title":"J Int AIDS Soc"},{"key":"469_CR21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00430-014-0350-5","volume":"203","author":"T Wolf","year":"2014","unstructured":"Wolf T, Fu\u00df B, Khaykin P, Berger A, Knecht G, Gute P et al (2014) Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis. Med Microbiol Immunol 203:409\u2013414","journal-title":"Med Microbiol Immunol"},{"key":"469_CR22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3109\/00365548.2012.690526","volume":"44","author":"M Gissl\u00e9n","year":"2012","unstructured":"Gissl\u00e9n M, Fuchs D, Hagberg L et al (2012) Cerebrospinal fluid viral breakthrough in two HIV infected subjects on darunavir\/ritonavir monotherapy. Scand J Infect Dis 44:997\u20131000","journal-title":"Scand J Infect Dis"},{"key":"469_CR23","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/QAD.0b013e32835646fb","volume":"26","author":"A Pasquet","year":"2012","unstructured":"Pasquet A, Ajana F, Melliez H et al (2012) Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS 26:1726\u20131728","journal-title":"AIDS"},{"key":"469_CR24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1089\/aid.2014.0014","volume":"30","author":"A Imaz","year":"2014","unstructured":"Imaz A, Cayuela N, Niub\u00f3 J et al (2014) Focal encephalitis related with viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir\/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir 30:984\u2013987","journal-title":"AIDS Res Hum Retrovir"},{"issue":"4 Suppl 3","key":"469_CR25","doi-asserted-by":"crossref","first-page":"19525","DOI":"10.7448\/IAS.17.4.19525","volume":"17","author":"A Antinori","year":"2014","unstructured":"Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A (2014) The PROTEA trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies\/mL. J Int AIDS Soc 17(4 Suppl 3):19525","journal-title":"J Int AIDS Soc"},{"key":"469_CR26","unstructured":"PROTEA Trial Investigators. A clinical trial comparing the efficacy of darunavir\/ritonavir monotherapy versus a triple combination therapy containing darunavir\/ritonavir and 2 nucleoside\/nucleotide reverse transcriptase inhibitors in patients with undetectable plasma HIV-1 RNA on current treatment (PROTEA). ClinicalTrials.gov-Identifier: NCT01448707; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01448707 . Accessed 18 Feb 2016"},{"key":"469_CR27","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2217\/hiv.10.24","volume":"4","author":"J Arribas","year":"2010","unstructured":"Arribas J, Hill A (2010) Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression. HIV Ther 4:1758","journal-title":"HIV Ther"},{"key":"469_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1310\/hct1503-79","volume":"15","author":"W Powderly","year":"2014","unstructured":"Powderly W, Hill A, Moecklinghoff C (2014) Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials. HIV Clin Trials 15:79\u201386","journal-title":"HIV Clin Trials"},{"issue":"15","key":"469_CR29","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","volume":"24","author":"C Gutmann","year":"2010","unstructured":"Gutmann C, Cusini A, G\u00fcnthard HF, Fux C, Hirschel B, Decosterd LA, Cavassi-ni M, Yerly S, Vernazza PL, Swiss HIV Cohort Study (SHCS) (2010) Randomized controlled study demonstrating failure of LPV\/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24(15):2347\u20132354","journal-title":"AIDS"},{"key":"469_CR30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/650538","volume":"50","author":"A Canestri","year":"2010","unstructured":"Canestri A, Lescure FX, Jaureguiberry S et al (2010) Discordance between cerebral spinal fluid and plasma HIV repli-cation in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773\u2013778","journal-title":"Clin Infect Dis"},{"key":"469_CR31","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","volume":"40","author":"J Arribas","year":"2005","unstructured":"Arribas J, Pulido F, Delgado R et al (2005) Lopinavir\/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. J Acquir Immune Defic Syndr 40:280\u2013287","journal-title":"J Acquir Immune Defic Syndr"},{"key":"469_CR32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1310\/hct1006-368","volume":"10","author":"E Nunes","year":"2009","unstructured":"Nunes E, Santini de Olveira M, Mercon M et al (2009) Monotherapy with lopinavir\/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomised, controlled, open-label pilot trial (KalMo Study). HIV Clin Trials 10:368\u2013374","journal-title":"HIV Clin Trials"},{"key":"469_CR33","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dks540","volume":"11","author":"J Bernardino","year":"2013","unstructured":"Bernardino J, Pulido F, Martinez E et al (2013) Switching to lopinavir-ritonavir with or without abacavir and lamivudine in lipoatrophic patients treated with zidovudine\/lamivudine\/abacavir. J Antimicrob Chemother 11:1373\u20131381","journal-title":"J Antimicrob Chemother"},{"key":"469_CR34","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/jac\/dkq327","volume":"65","author":"J Meynard","year":"2010","unstructured":"Meynard J, Bouteloup V, Landman R et al (2010) Lopinavir\/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 65:2436\u20132444","journal-title":"J Antimicrob Chemother"},{"key":"469_CR35","doi-asserted-by":"crossref","unstructured":"Reinheimer C, Wesner A, Keppler OT, Doerr HW, Herrmann E, St\u00fcrmer M et al. (2016) Prevalence of K65R in Patients Treated with Tenofovir Disoproxil Fumarate: Recommendations Based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD). Med Microbiol Immunol. 2016 Jan 8. [Epub ahead of print]. PMID: 26746222","DOI":"10.1007\/s00430-015-0448-4"},{"issue":"13","key":"469_CR36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1097\/00002030-200309050-00008","volume":"17","author":"C Eggers","year":"2003","unstructured":"Eggers C, Hertogs K, St\u00fcrenburg HJ, van Lunzen J, Stellbrink HJ et al (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17(13):1897\u20131906","journal-title":"AIDS"},{"issue":"4","key":"469_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00430-015-0419-9","volume":"204","author":"MO K\u00f6ksal","year":"2015","unstructured":"K\u00f6ksal MO et al (2015) HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey. Med Microbiol Immunol 204(4):551\u2013555. doi: 10.1007\/s00430-015-0419-9 (Epub 2015 Apr 28)","journal-title":"Med Microbiol Immunol"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-016-0469-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00430-016-0469-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-016-0469-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T01:33:42Z","timestamp":1656898422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-016-0469-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s00430-016-0469-7","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}